Orexo to assess suitability of its AmorphOx technology for dry powder nasal formulations of SVF’s LNP-encapsulated mRNA vaccines

Orexo has announced that it will evaluate the ability of its AmorphOX dry powder platform to create stable formulations of SVF’s LNP-encapsulated mRNA vaccines for nasal delivery. Orexo has its own pipeline of intranasal dry powder drugs, including a dry powder nasal flu vaccine that it is developing with Abera Bioscience.

According to the announcement, the project is “part of Orexo’s strategy to evaluate AmorphOX across additional therapeutic areas and molecule classes.” Orexo’s own pipeline primarily includes rescue medications, including OX124 intranasal dry powder naloxone for the reversal of opioid overdose. The company recently announced that the FDA has accepted an NDA for the naloxone product, now called Izipry. The pipeline also includes OX390 for the reversal of opioid overdose and OX640 intranasal dry powder epinephrine for the treatment of anaphylaxis.

Orexo President and CEO Nikolaj Sørensen commented, “This collaboration will explore whether AmorphOX can address an important formulation challenge in mRNA vaccine development. Our initial objective is to establish whether we can develop stable powder-based formulations while preserving LNP integrity and mRNA activity. Positive results would provide a foundation for further development and help us assess the potential of our technology in vaccines and other biologic applications.”

SVF Vaccines Chief Scientific Officer Matti Sällberg said, “The clinical success of mRNA vaccines has highlighted both the enormous promise and the formulation challenges associated with these technologies. The ability to convert LNP-mRNA formulations into a stable dry powder suitable for nasal administration could represent an important advancement for the field. Intranasal vaccination offers an opportunity to generate immunity where respiratory pathogens enter the body. This collaboration is an important first step toward exploring how our mRNA vaccine expertise and Orexo’s formulation capabilities could support that goal.”

Read the Orexo press release

Share

published on

December 9-December 11: DDL 2026, Edinburgh, Scotland

April 27-30: RDD Europe 2027, Antibes, France

May 30-June 2: ISAM Congress 2027, Dublin, Ireland

June 23: SMI London, London, UK